European regulators want to know more about the risks of GLP-1 drugs
Bio Pharma Dive
DECEMBER 1, 2023
The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts.
Let's personalize your content